5-fluoro-3-(4-methoxyphenyl)-1-methyl-8-propoxy-1H-quinolin-4-one | 1092496-06-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-fluoro-3-(4-methoxyphenyl)-1-methyl-8-propoxy-1H-quinolin-4-one
• 英文别名: 5-fluoro-3-(4-methoxyphenyl)-1-methyl-8-propoxyquinolin-4-one
• CAS: 1092496-06-4
• 化学式: C₂₀H₂₀FNO₃
• 分子量: 341.382
• InChiKey: SLMIOCUVHNEMBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-fluoro-2-nitro-1-propoxybenzene 在 5%-palladium/activated carbon Amberlyst 15 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 苯 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 35.25h， 生成 5-fluoro-3-(4-methoxyphenyl)-1-methyl-8-propoxy-1H-quinolin-4-one
  参考文献：
  名称：

  WO2008/150029

  摘要：

  公开号：

文献信息

• [EN] QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION<br/>[FR] COMPOSÉ DE QUINOLONE ET AGENT PHARMACEUTIQUE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010064735A1

  公开（公告）日：2010-06-10

  The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.

  本发明提供了一种喹诺酮化合物，该化合物能够抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，以便在延长给予L-多巴的时间的同时改善神经元功能；本发明的喹诺酮化合物由公式(1)表示：其中：R1代表氢等；R2代表氢等；R3代表取代或未取代的苯基等；R4代表卤素等；R5代表氢等；R6代表氢等；R7代表氢等。
• Quinolone compound and pharmaceutical composition
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US08269011B2

  公开（公告）日：2012-09-18

  The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R4 represents a halogen atom; R5 represents a hydrogen atom or halogen atom; R6 represents a hydrogen atom; and R7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.

  本发明提供一种喹诺酮化合物，其由通式（1）表示或其盐，其中R1代表氢原子等；R2代表氢原子等；R3代表苯基，可选地被一个或多个取代基取代等；R4代表卤原子；R5代表氢原子或卤原子；R6代表氢原子；R7代表羟基等。该喹诺酮化合物具有功能改善效果，通过抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而延长首次给药前的期间，抑制神经功能障碍的进展。
• QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
  申请人：Otsubo Kenji

  公开号：US20100130546A1

  公开（公告）日：2010-05-27

  The present invention provides a quinolone compound represented by General Formula (1) or a salt thereof, wherein R 1 represents a hydrogen atom, etc.; R 2 represents a hydrogen atom, etc.; R 3 represents a phenyl group optionally being substituted with one or more substituents, etc.; R 4 represents a halogen atom; R 5 represents a hydrogen atom or halogen atom; R 6 represents a hydrogen atom; and R 7 represents a hydroxyl group, etc. The quinolone compound have a functional improvement effect, which suppresses progression of neurological dysfunction by inhibiting the chronic progression of Parkinson's disease or protecting dopamine neurons from the disease etiology, thereby prolonging the period before first administration begins.

  本发明提供了一种喹诺酮化合物，其由通式（1）或其盐所表示，其中R1表示氢原子等；R2表示氢原子等；R3表示苯基，该苯基可以选择性地被一个或多个取代基取代等；R4表示卤素原子；R5表示氢原子或卤素原子；R6表示氢原子；R7表示羟基等。该喹诺酮化合物具有功能改善效果，通过抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而延长首次给药前的期间，抑制神经功能障碍的进展。
• US8269011B2
  申请人：——

  公开号：US8269011B2

  公开（公告）日：2012-09-18
• US8304546B2
  申请人：——

  公开号：US8304546B2

  公开（公告）日：2012-11-06